Ma Songjiang's Form 4 filing
Gyre Therapeutics, Inc. (GYRE) · filed Dec 26, 2024
- Accession no.
- 0001140361-24-050413
- Filed
- Dec 26, 2024
- Trade date
- Dec 23-24, 2024
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $48.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ma SongjiangCIK 0001985547 | Director, Officer (President) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 23, 2024 | Common Stock | SSaleDisposed | −1,704 | $12.24 | −$20,856.96 | 2,932,763 | Indirect | |
| Dec 23, 2024 | Common Stock | SSaleDisposed | −296 | $12.44 | −$3,682.24 | 2,932,467 | Indirect | |
| Dec 24, 2024 | Common Stock | SSaleDisposed | −2,000 | $11.93 | −$23,860 | 2,930,467 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.